CEBPZ and acute myeloid leukemia: While the outcome of secondary or therapy-related acute promyelocytic leukemia (APL), another member of the good-prognosis AML subsets, is similar to de novo APL, the outcome of secondary or therapy-related CBF AML (tCBF-AML) is significantly worse than de novo CBF AML [46, 47].